IP Library › Granted Patent US 11,965,008
Granted Patent B2
US 11,965,008 · App. 17/386,047 · Granted Apr 23, 2024

IL-2 muteins and uses thereof

Inventors: Nathan Higginson-Scott (Watertown, MA); Joanne L. Viney (Watertown, MA); Jyothsna Visweswaraiah (Cambridge, MA); Erik Robert Sampson (Watertown, MA); Kevin Lewis Otipoby (Watertown, MA)
Assignee: PANDION OPERATIONS, INC.
C07K14/55A61K38/00C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,965,008
App. No.
17/386,047
Granted
Apr 23, 2024
Kind
B2
Abstract

The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.

Claims (19)

1. A method of treating atopic dermatitis or Systemic Lupus Erythematosus (SLE), in a subject, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a polypeptide comprising an amino acid sequence of SEQ ID NO: 26, and a pharmaceutically acceptable carrier.

2. The method of claim 1 , wherein the polypeptide further comprises a linker peptide at the C-terminus.

3. The method of claim 2 , wherein the linker peptide comprises the sequence of (GGGGS) n , wherein n is 1, 2, 3, or 4.

4. The method of claim 1 , wherein the polypeptide further comprises a Fc region.

5. The method of claim 4 , wherein the Fc region comprises the sequence of SEQ ID NO: 8 or SEQ ID NO: 15.

6. The method of claim 4 , wherein the Fc region is at the C-terminus of the polypeptide comprising SEQ ID NO: 26.

7. The method of claim 4 , wherein the Fc region is at the N-terminus of the polypeptide comprising SEQ ID NO: 26.

8. The method of claim 1 , wherein the peptide further comprises a linker peptide that links the polypeptide of SEQ ID NO: 26 and a Fc region.

9. The method of claim 8 , wherein the linker peptide is (GGGGS) n , n is 1, 2, 3, or 4.

10. The method of claim 9 , wherein n is 4.

11. The method of claim 10 , wherein the Fc region comprises the sequence of SEQ ID NO: 8 or SEQ ID NO: 15.

12. The method of claim 11 , wherein the Fc region is at the C-terminus of the polypeptide of SEQ ID NO: 26.

13. The method of claim 11 , wherein the Fc region is at the N-terminus of the polypeptide of SEQ ID NO: 26.

14. The method of claim 1 , wherein the polypeptide comprises a sequence of SEQ ID NO: 39.

15. The method of claim 1 , wherein the polypeptide consists of a sequence of SEQ ID NO: 39.

16. The method of claim 1 , wherein the pharmaceutical composition comprises a dimer of a polypeptide comprising the amino acid sequence of SEQ ID NO: 39.

17. The method of claim 1 , wherein the pharmaceutical composition comprises a dimer of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 39.

18. The method of claim 1 , wherein the subject is treated for atopic dermatitis.

19. The method of claim 1 , wherein the subject is treated for Systemic Lupus Erythematosus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2022
From: HIGGINSON-SCOTT, NATHAN; VINEY, JOANNE L; VISWESWARAIAH, JYOTHSNA; SAMPSON, ERIK R; OTIPOBY, KEVIN L
To: PANDION OPERATIONS, INC.
Reel/Frame 060740/0450 →
Continuity (6)
Continuation 16693741 · Nov 25, 2019
Continuation 16229133 · Dec 21, 2018
Continuation 16109897 · Aug 23, 2018
Provisional Application 62675972 · May 24, 2018
Provisional Application 62595357 · Dec 6, 2017
Related Publication 20220195003A1 · Jun 23, 2022